Companion Diagnostics

Randox Biosciences is the ideal CDx partner as with over 220 FDA cleared and over 700 CE marked assays, we offer the full package of diagnostic and CDx assay development, optimisation and regulatory approval.

Built on this IVD heritage, Randox Biosciences is actively involved in a broad range of CDx development projects in therapeutic areas including oncology, CNS, ophthalmology, inflammation and infection.

  • Soluble Biomarkers (serum and plasma)
    • Single analyte protein
    • Multiplex protein
    • Small molecules (& metabolites)
  • Molecular Biomarkers (DNA & RNA)
    • Multiplex mutation & SNP arrays
    • Infectious diseases
  • A range of CDx platform options
    • Clinical chemistry assays & instrumentation
    • Immunoassay assays & instrumentation (including multiplexing)
    • Molecular assays & instrumentation (including multiplexing)
  • An unrivalled existing IVD & RUO biomarker test menu offering rapid IUO assay development
  • Full life sciences/biotechnology service (monoclonal, polyclonal, single chain Fv antibodies and recombinant protein manufacture)
  • Global distribution and operations in over 145 countries ensuring no block to commercial adoption of the CDx
  • QC, calibrators and proficiency testing solutions to support the CDx assay
  • Central laboratory services
  • Technical support & engineering
  • Established agreements with leading global CRO’s for CDx pivotal trials
  • Full regulatory support at Randox for FDA, PMA, CE and all key international regulatory authorities

Development Plan

companion-diagnostics

We are uniquely positioned with the capabilities to bring your project from antibody development right through to global commercialisation

If you are interested in discussing a potential CDx collaboration with Randox Biosciences,
please contact one of the team on:
Tel UK: +44 (0) 28 9442 2413
E-mail: info@randoxbiosciences.com

Get in touch to discover more